Skip to main content
Neuro-Oncology logoLink to Neuro-Oncology
. 2018 Jun 22;20(Suppl 2):i136. doi: 10.1093/neuonc/noy059.481

MBRS-36. IDENTIFICATION OF TWO PROTEIN-SIGNALING STATES DELINEATING TRANSCRIPTIONALLY HETEROGENEOUS HUMAN MEDULLOBLASTOMA

Walderik Zomerman 1, Sabine Plasschaert 2, Siobhan Conroy 1, Frank Scherpen 1, Tiny Meeuwsen-de Boer 1, Harm-Jan Lourens 1, Sergi Guerrero Llobet 1, Marlinde Smit 1, Lorian Slagter-Menkema 1, Annika Seitz 1, Corrie Gidding 3, Esther Hulleman 4, Pieter Wesseling 4,2, Lisethe Meijer 1, Leon van Kempen 1,5, Anke van den Berg 1, Daniel Warmerdam 1, Frank Kruyt 1, Floris Foijer 1, Marcel van Vugt 1, Wilfred den Dunnen 1, Eelco Hoving 2, Victor Guryev 1, Eveline de Bont 1, Sophia Bruggeman 1
PMCID: PMC6012173

Abstract

Medulloblastoma consists of different transcriptional subgroups. To characterize medulloblastoma at the phosphoprotein-signaling level, we performed high-throughput peptide phosphorylation profiling on a cohort of SHH, Group 3 and Group 4 medulloblastomas. We identified two major protein-signaling profiles. One profile was associated with rapid death post-recurrence and resembled MYC-like signaling for which MYC lesions are sufficient but not necessary. The second profile showed DNA damage, apoptotic and neuronal signaling. Integrative analysis demonstrated that heterogeneous transcriptional input converges on these protein-signaling profiles: all SHH and a subset of Group 3 patients exhibited the MYC-like protein-signaling profile, the other Group 3 subset and Group 4 patients displayed the DNA damage/apoptotic/neuronal signaling profile. Functional analysis highlighted cell cycle progression and protein synthesis as therapeutic targets for MYC-like medulloblastoma.


Articles from Neuro-Oncology are provided here courtesy of Society for Neuro-Oncology and Oxford University Press

RESOURCES